BiomericaNASDAQ: BMRA

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Biomerica is in the Healthcare sector

Biomerica is in the Medical Devices industry

Biomerica is headquartered in United States

Biomerica initial public offering (IPO) was on 07 September 1984

https://www.biomerica.com

No, Biomerica is not included in the S&P 500 index

No, Biomerica is not included in the NASDAQ 100 index

No, Biomerica is not included in the Dow Jones index